title: [Clinical controlled trial of first-line treatment for advanced kidney cancer].
abstract: OBJECTIVE
  To estimate the efficacies of different first-line treatments for advanced stage kidney cancer.
  
  
  METHODS
  For this observation controlled trial, a total of 82 cases with advanced stage kidney cancer from 2006 to 2011 were recruited. They were divided into 3 groups and accepted gemcitabine plus interleukin-2 (IL-2) (Group A), oxaliplatin plus capecitabine (Group B) or sorafenib alone (Group C).
  
  
  RESULTS
  Among them, 76 patients had complete data. The overall response rates of A-C groups were 39.3% (11/28), 37.0% (10/27) and 38.1% (8/21) respectively. And there was no significant difference (χ(2) = 0.029, P = 0.986). And their progression-free survival (PFS) rates were 9.1 (95%CI: 7.9 - 10.3), 7.5(95%CI: 5.5 - 9.5) and 10.9 (95%CI: 10.5 - 11.3) months respectively. And there were significant differences (P = 0.013). Average daily treatment costs were 490, 498 and 501 Chinese yuan respectively. And there was no significant difference (P = 1.240). Because of toxicity, 2 and 3 cases withdrew in Groups A and B respectively.
  
  
  CONCLUSIONS
  Gemcitabine plus IL-2 and oxaliplatin plus capecitabine have similar early efficacies and tolerance profiles for the patients who can not accept sorafenib as first-line treatment.
authors: Department of Oncology, General Hospital of Shenyang Military Region, Shenyang, China.
authors: Zhen-Dong
authors: ZD
authors: Zheng
authors: Shu-Xian
authors: SX
authors: Qu
authors: Yong-Ye
authors: YY
authors: Liu
authors: Hui
authors: H
authors: Hao
authors: Guo-Jing
authors: GJ
authors: Zhang
authors: Xiao-Dong
authors: XD
authors: Xie
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D016896:Treatment Outcome